Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice

URN to cite this document:: urn:nbn:de:bvb:355-epub-479069
DOI to cite this document:: 10.5283/epub.47906

Harloff, Manuela ; Prüschenk, Sally ; Seifert, Roland ; Schlossmann, Jens

License: Creative Commons Attribution Non-commercial No Derivatives 3.0
PDF - Published Version
(23kB)

Date of publication of this fulltext: 30 Aug 2021 10:34

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Background and Purpose Diabetic nephropathy is the leading cause for end-stage renal disease worldwide. Until now, there is no specific therapy available. Standard treatment with inhibitors of the renin-angiotensin system just slows down progression. However, targeting the NO/sGC/cGMP pathway using sGC activators does prevent kidney damage. Thus, we investigated if the sGC activator cinaciguat ...